title: Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
abstract: OBJECTIVE
  To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging.
  
  
  METHODS
  From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar® 15 mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups was injected intravenously for 14 days.
  
  
  RESULTS
  Treatment effectiveness in the two groups differed with statistical significance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p>0.05).
  
  
  CONCLUSIONS
  The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.
authors.affiliation: Department of Oncology, Maanshan City People's Hospital, Maanshan, China E-mail : Zhangfenglin@csco.org.cn.
authors.forename: Feng-Lin
authors.initials: FL
authors.lastname: Zhang
authors.forename: Er-Yun
authors.initials: EY
authors.lastname: Gao
authors.forename: Rong-Bao
authors.initials: RB
authors.lastname: Shu
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Peng
authors.initials: P
authors.lastname: Sun
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.forename: Bang-Qin
authors.initials: BQ
authors.lastname: Jiang
authors.forename: Shuang-Qi
authors.initials: SQ
authors.lastname: Chen
authors.forename: Fang-Bo
authors.initials: FB
authors.lastname: Cui
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003503:Cyclobutanes / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D004334:Drug Administration Schedule; D043169:Endostatins / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000068437:Pemetrexed / Q000008:administration & dosage; D055420:Perfusion Imaging; D011994:Recombinant Proteins / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D014055:Tomography, Emission-Computed; D000093542:Gemcitabine
chemical_list: D003503:Cyclobutanes; D043169:Endostatins; D009944:Organoplatinum Compounds; D011994:Recombinant Proteins; D043823:Taxoids; D000068437:Pemetrexed; D003841:Deoxycytidine; D000077143:Docetaxel; C522911:endostar protein; C066228:lobaplatin; D002945:Cisplatin; D000093542:Gemcitabine